<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055249</url>
  </required_header>
  <id_info>
    <org_study_id>XPM-024</org_study_id>
    <nct_id>NCT01055249</nct_id>
  </id_info>
  <brief_title>UVB Model Validation Study</brief_title>
  <official_title>Single Centre, Subject and Observer Blinded, Placebo Controlled, Cross-over Study of the Effect of Oral Ibuprofen and Topical Hydrocortisone-21-acetate on Ultraviolet Radiation (UVR) Induced Pain and Inflammation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>X-pert Med GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>X-pert Med GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single centre, subject and observer blinded, placebo controlled, cross-over study of the
      effect of oral ibuprofen and topical hydrocortisone-21-acetate on ultraviolet radiation (UVR)
      induced pain and inflammation in healthy volunteers conducted in two segments and using an
      intra-individual comparison of application areas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single centre, subject and observer blinded, placebo controlled, cross-over study of the
      effect of oral ibuprofen and topical hydrocortisone-21-acetate on ultraviolet radiation (UVR)
      induced pain and inflammation in healthy volunteers conducted in two segments and using an
      intra-individual comparison of application areas.

      Subjects that signed the informed consent and are eligible to the study will be irradiated on
      the back to evaluate their individual minimal erythema doses (MEDs). Read out to determine
      MED will be done within 24 h after UVR.

      A training session (without study medication) using the MED definition areas will be
      performed in order to introduce subjects to the testing and rating procedures.

      Subjects will come in within 14 days of screening to start the first Segment of the study.
      Eligible subjects will be randomised to receive either:

        1. IB 600 mg, applied orally b.i.d., or

        2. OP, applied orally b.i.d.

      Allocation of topical treatment to these areas will be randomly assigned to:

        1. PG, 15 μl/cm2 applied topically b.i.d., or

        2. HC, 15 μl/cm2 applied topically b.i.d.

      Defined areas will be irradiated with defined dosages of UVR. Assessment of hyperalgesia to
      heat and signs of inflammation (erythema, skin temperature) for all areas will be performed.

      Subjects return within 4 to 11 days to the study site for the second segment of the study.
      Treatment allocation will be crossed-over and new treatment areas will be selected on the
      back.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperalgesia to heat</measure>
    <time_frame>72 h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erythema, Skin temperature</measure>
    <time_frame>72 h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pain</condition>
  <condition>Inflammation</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ibuprofen 600 mg (active comparator); Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Oral Placebo (placebo comparator), Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen, Hydrocortisone</intervention_name>
    <description>Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>X-pert Med GmbH</name>
      <address>
        <city>Graefelfing</city>
        <state>Bavaria</state>
        <zip>82166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.x-pert-med.de</url>
    <description>link to Sponsor and investigational site</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2010</study_first_submitted>
  <study_first_submitted_qc>January 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2010</study_first_posted>
  <last_update_submitted>July 12, 2010</last_update_submitted>
  <last_update_submitted_qc>July 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ilka Rother, MD</name_title>
    <organization>X-pert Med GmbH</organization>
  </responsible_party>
  <keyword>UVB</keyword>
  <keyword>pain</keyword>
  <keyword>inflammation</keyword>
  <keyword>model</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>Ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 28, 2011</submitted>
    <returned>July 27, 2011</returned>
    <submitted>August 1, 2011</submitted>
    <returned>August 29, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

